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Capsule: 
Background: Raising ADAM10 alpha-secretase 
activity has been considered as an attractive 
therapeutic option in Alzheimer’s disease. 
Results: Administration of prodomain of ADAM9 
(ProA9) prevents ADAM10 shedding and 
increases membrane alpha secretase activity in a 
neuronal cell line.  
Conclusion: Use of ProA9 is a mean to modulate 
cellular ADAM10 activity 
Significance: ProA9 can be used in vivo to 
increase ADAM10 alpha secretase activity.  
 
Prodomains of ADAM metallopeptidases can 
act as highly specific intra- and intermolecular 
inhibitors of ADAM catalytic activity. The 
mouse ADAM9 prodomain (proA9; amino acid 
24-204), expressed and characterized from E. 
coli, is a competitive inhibitor of human 
ADAM9 catalytic/disintegrin domain with an 
overall inhibition constant of 280±34nM and 
high specificity towards ADAM9. In SY5Y 
neuroblastoma cells over-expressing amyloid 
precursor protein (APP), proA9 treatment 
reduces the amount of endogenous ADAM10 
enzyme in the media whilst increasing  
 
membrane-bound ADAM10 as shown both by 
Western and activity assays with selective 
fluorescent peptide substrates using proteolytic 
activity matrix analysis (PrAMA). An increase 
in membrane-bound ADAM10 generates higher 
levels of soluble amyloid precursor protein 
alpha (sAPPα) in the media, whereas sAPPβ  
levels are decreased, demonstrating that 
inhibition of ADAM9 increases α-secretase 
activity on the cell membrane. Quantification of 
physiological ADAM10 substrates by a 
proteomic approach revealed that substrates 
such as epidermal growth factor (EGF), HER2,  
osteoactivin, and CD40-Ligand are increased in 
the media of BT474 breast tumor cells that 
were incubated with proA9, demonstrating that  
the regulation of ADAM10 by ADAM9 applies 
for many ADAM10 substrates. Taken together, 
our results demonstrate that ADAM10 activity 
is regulated by inhibition of ADAM9 and this 
regulation may be used to control shedding of 
APP by enhancing α-secretase activity, a key 
regulatory step in the aetiology of Alzheimer’s 
disease.  
 http://www.jbc.org/cgi/doi/10.1074/jbc.M111.280495The latest version is at 
JBC Papers in Press. Published on September 28, 2011 as Manuscript M111.280495
 Copyright 2011 by The American Society for Biochemistry and Molecular Biology, Inc.
 at M
assachusetts Institute of Technology, on Decem
ber 13, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
 2 
Members of the ADAM (a disintegrin and 
metalloproteinase) family of proteinases function 
as sheddases by cleaving type I and type II integral 
single membrane proteins to generate soluble 
forms of these proteins(1,2). In addition to their 
catalytic and disintegrin domains, ADAM family 
members contain a prodomain that is required for 
expression, folding, and efficient transport of the 
proteinase(3). ADAM prodomains are efficient 
and highly specific inhibitors for their cognate 
ADAM proteases and even when proteolytically 
cleaved from their nascent polypeptides they can 
still serve as intermolecular inhibitors of their 
respective ADAM proteins(4,5). ADAM 
proteinases have functions in the etiologies of a 
variety of diseases and conditions. ADAM17 and 
10, for example are known sheddases for over 40 
different type I and II integral membrane 
proteins(6,7)  and improper regulation of their 
catalytic activities is implicated in neurological 
diseases (8,9), carcinogenesis(10-12), and  
inflammatory conditions(13-18). In particular, the 
cleavage of Amyloid Precursor protein at the alpha 
secretase site is considered as instrumental in 
prevention of AD by favoring the non-
amyloidogenic pathway(19). In neurons, 
ADAM10 has been demonstrated to be essential 
for the alpha secretase step of APP processing(20). 
Therefore means to control α-secretase levels are 
of therapeutic relevance in AD.  
 
Understanding the hierarchy of ADAM 
proteinases could aid in determining broader 
biological mechanisms and reveals an additional 
level of ADAM regulation. For example, Cisse et 
al., demonstrated using transfection experiments 
that ADAM10 alpha secretase activity in mouse 
embryonic fibroblasts (MEFs) and a neuronal cell 
line, could be increased by ADAM9 
overexpression, possibly by affecting the shedding 
or release of ADAM10 from the membrane of 
cells(21). Recently, Tousseyn et al. provided direct 
evidence that ADAM9 and ADAM15 process 
ADAM10 leaving behind an intracellular 
cytoplasmic domain ICD (22) with a potential 
function in regulating transcription of genes in the 
cell nucleus. This type of cleavage event is known 
as regulated intramembrane proteolysis or 
“RIP”(23). However, the physiological 
consequences of this cleavage step have remained 
elusive. A specific inhibitor of ADAM9 could be 
used to elucidate the physiological consequence of  
ADAM10 shedding, i.e. to investigate a possible 
regulation of ADAM10 dependent shedding 
events. 
  
Typically, forced expression of ADAM family 
members in MEFs derived from knockout mice, 
and siRNA mediated silencing have been used as 
tools to validate the role of a particular disintegrin 
metalloproteinase in shedding events. We have 
chosen to use specific inhibitors in order to 
understand how modulation of only the enzyme’s 
catalytic activity affects cellular processing as with 
pharmaceutical agents, activities oftentimes are 
regulated while the gene product remains intact. 
To date, the only available specific inhibitors of 
ADAM family members are small molecules 
described by Incyte(24,25), and protein 
therapeutics using modified tissue inhibitor of 
metalloproteinases(26), the prodomains’ of 
ADAM17 and 10(4,5), and an antibody to 
ADAM17(27). Therefore, studies were undertaken 
to express, refold, purify, and examine a 
prodomain construct based on ADAM9 to easily 
achieve the highest degree of specificity for 
ADAM9 inhibition. A number of parameters were 
varied to obtain prodomain in milligram quantities 
that had refolded properly as assessed by 
inhibition studies with ADAM9. We demonstrate 
that the prodomain is a specific inhibitor of 
ADAM9 and show that ADAM9 regulates the 
cellular activity of ADAM10. Furthermore, proA9 
was also used as a tool to demonstrate that specific 
inhibition of endogenous ADAM9 catalysis 
increases shedding of ADAM10 substrates in 
cellular assays. 
 
Experimental Procedures 
Materials 
Human recombinant ADAM9, ADAM8, 
ADAM10, ADAM12 and ADAM17 proteases 
containing the catalytic/disintegrin domains, 
respectively, were obtained from R&D Systems 
(Minneapolis, MN). All oligonucleotides for PCR 
were synthesised from IDT DNA (Coralville, IA). 
 
Methods 
Cloning of ADAM9 cDNA- A DNA fragment 
containing ADAM9 prodomain (24-204) was 
cloned into a modified PET vector at the Nde1, 
BamH1 restriction sites. The modified PET vector 
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encodes His6 between NdeI and BamHI sites to 
produce a protein with a N-terminal His-tag.  
DNA primers were: N-His (24-204), 5’ primer, 
GGA GCC CAT ATG CCA GTC CTC GAG 
GCC GGG CGA, 3’ primer, GGA GCC GGA 
TCC TTA TCT GCG CAG CTG AGT GAC ; N-
His (24-204). 
 
Expression and Purification of soluble 
Prodomain-The construct was transformed into E. 
coli strain BL21(DE3)STAR (Invitrogen, 
Carlsbad, CA). For a typical sample preparation, 
bacteria were grown in 4 x 1 litre of luria broth 
(LB) at 37ºC until the OD600 reached 0.4. The 
culture was incubated at 20oC for 30 min before 
adding IPTG (1 mM) to induce protein expression. 
Cells were harvested after 16 hours by spinning at 
4oC for 30 min at 4000 rpm in a Sorvall JA 10 
rotor. The supernatant was removed and pellets 
were either stored at -70oC or used directly. 
 
Cell pellets were lysed in 30 ml of buffer 
containing 50 mM phosphate, pH 8.0, 10 mM 
imidazole, 0.05% β-mercaptoethanol, and 300 mM 
NaCl at 4 ºC containing cell lytic (Sigma-Aldrich) 
(3 ml of a 10x concentrated solution). Lysed 
bacteria were sonicated to shear the DNA and 
RNA, and then polyethyleneimine was added to 
0.1% to precipitate the DNA. Samples were 
centrifuged at 13,000 rpm for 30 minutes. The 
cleared supernatant was applied to 1 ml of 
TALON resin (Clontech, Mountain View, CA) 
pre-equilibrated with lysis buffer without cell 
lysate. After two 5 ml washes with lysis buffer and 
50 mM phosphate, pH 8.0 containing 20 mM 
imidazole, 0.05% β-mercaptoethanol, and 300 mM 
NaCl, the protein was eluted with a solution 
containing 50 mM phosphate, pH 8.0, 150 mM 
imidazole, 0.05% β-mercaptoethanol, and 300 mM 
NaCl. The eluted protein was concentrated using 
an Amicon ultra filtration device (molecular 
weight cutoff 10 kDa) from Millipore (Billerica, 
MA) and further purified with a Sephacryl-S200 
column (320 ml) on an Akta FPLC system at a 
flow rate of 1 ml/min. FPLC buffers contained 25 
mM Tris, pH 8.0, 100mM NaCl and 0.05% β-
mercaptoethanol. Fractions containing protein 
were concentrated and passed through an Endotrap 
blue column from Profos to remove endotoxin and 
then stored as 10% glycerol stocks at -80 oC.  
Expression, Refolding, and Purification of 
insoluble Prodomain- Colonies of freshly 
transformed ArcticExpress™ (Agilent 
Technologies, Santa Clara, CA) or BL21(DE3) 
(Invitrogen, Carlsbad, CA) were used in all 
refolding  and expression experiments. Cells from 
a 1L overnight culture grown in LB containing 
ampicillin and gentamycin, were centrifuged at 
5,500 x g and re-suspended in 50 mL LB broth. 
Twenty-five millilitres of this suspension was used 
to inoculate one litre of LB containing ampicillin. 
For the ArcticExpress conditions, cultures were 
incubated at 10°C with shaking for 2 hours, 
induced by adding IPTG to 0.2 mM, and grown 
for an additional 20 hours. Cells were harvested by 
centrifugation for 15 min at 5,500 x g at 4°C. 
Inclusion bodies containing proA9 were isolated 
from cells lysed in 5 volumes of Bug Buster 
Master Mix (Novagen), 0.5mg/ml of lysozyme 
(Sigma-Aldrich), 5 mM MgCl2 and 5 mM NaATP, 
containing Complete™ EDTA-free proteinase 
inhibitors (Roche Diagnostics), per gram of cell 
paste. The lysis suspension was incubated 30 min 
at room temperature with gentle agitation, and 
centrifuged for 30 min at 16,000 x g at 4°C to 
collect the inclusion bodies.  Purification of 
inclusion bodies was accomplished by washing 
twice vs. 5 vol of 0.1x Bug Buster Master Mix and 
2 times vs. 5 volumes of water.  The resulting 
pellets were resuspended in water or 50mM Tris-
Cl, pH 8.0 and stored frozen at -80°C. 
Refolding conditions were established using the 
HiPER-FOLD™ Starter kit from Barofold. 
 
Using the best refolding conditions determined 
above,  inclusion bodies were added to buffer 
containing 50mM CHES, pH9 and 5mM TCEP, 
and then placed under pressure in a Barofold 
apparatus for 24hr at room temperature. Soluble 
protein after the pressure was released, was 
purified further by passage through 10 ml of Ni-
NTA resin (Qiagen, Valencia, CA) followed by 
washes of 10 and 20 mM imidazole, and elution 
with 250 mM imidazole in buffers that contained 
4mM TCEP, 50 mM NaPi, pH 8, and 300 mM 
NaCl.  The eluted protein was concentrated to less 
than 5 ml using an Amicon ultra filtration device 
(molecular weight cutoff 10 kDa) from Millipore 
(Billerica, MA) and further purified with a 
Sephadex-16/60 column (120 ml) on an Akta 
FPLC system at a flow rate of 1 ml/min. FPLC 
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buffers contained 25 mM Tris, pH 8.0, 100 mM 
NaCl and 4 mM TCEP. Fractions containing 
protein were concentrated, passed through an 
Endotrap Blue column from Hyglos/Profos, and 
stored as 10% glycerol stocks at -80oC. In some 
experiments, proA9 was refolded from inclusion 
bodies from BL21(DE3) purified via a Ni column 
and then dialyzed against 25mM CHES, pH9, 
100mM NaCl and 0.035% beta mercaptoethanol 
or passed through a Sephadex- 16/60 column 
using the same buffer conditions. In addition, 
proA9 was sometimes refolded from urea after 
purification with Ni-NTA agarose, and then 
further purified via a Sephadex 16/60 column. 
Inhibition assays- Fluorescence intensities were 
measured every 2 minutes at excitation and 
emission wavelengths of 485 and 530 nm, 
respectively at room temperature in black coated 
96 well plates using a top to bottom Fluoroskan II 
fluorometer. Activity of TACE catalytic-
disintegrin, ADAM8, ADAM12 and ADAM10 
catalytic/disintegrin recombinant proteins was 
monitored as previously described using the 
fluorescent substrate PEPDab005 (28). Inhibition 
assays were done using up to 8.4 µM proA9. 
ADAM9 activity was assayed using the 
fluorescent substrate PEPDab010 (29) in 70µl of 
buffer with 5µl of proA9 (75-8000 nM final) or 
buffer control. For each proA9 concentration, a 
well containing only proA9 and substrate were 
used to correct for fluorescence fluctuations due to 
the prodomain itself. ADAM9 was provided as a 
0.1 µg/µl stock solution, which was diluted 1:50 
from which 8 µl was added to start the reaction. 
The functional purity of ADAM9 was confirmed 
by using hydroxamate inhibitors and the 
determination of IC50s which were compared to 
literature values(29).   
 
Measurement of ADAM10 activity in the media 
and in membrane fractions- SY5Y neuroblastoma 
cells were cultured in duplicate using a 6 well 
plate for 24 hr in serum free media with proA9 
(5µM) or a buffer control. Media was removed 
and spun to remove cell fragments, and set aside 
for assaying.  Cells were washed with PBS and 
then scraped from the plate and resuspended in a 
1.5ml tube in a cold solution of 0.25M sucrose, 
50mM Tris, pH8, and a protease inhibitor cocktail 
from Roche Diagnostics. Cells were broken via 
pipetting up and down, and the suspension was 
spun at 13,000 x g to pellet the membranes which 
were resuspended and washed with sucrose buffer. 
After pelleting, membranes were resuspended in 
200µl of sucrose buffer per well of cells. Protein 
concentrations were determined using the BioRad 
BPA assay.  
The media and membrane suspension were tested 
for ADAM10 activity by using the Proteolytic 
Activity Matrix Analysis (PrAMA) technique 
developed by Miller (30) using substrates 
PEPDab005, PEPDab010, PEPDab008, 
PEPDab013, PEPDab014 that varied in their 
specificities towards different ADAM family 
members and MMPs. Briefly, 12.5 µM substrate 
concentrations in ADAM buffer, 60µl, were 
incubated with either 20 µl of media or 10µl of 
resuspended membranes. Fluorescence units vs. 
time were monitored with a Fluostar BMG Optima 
using excitation and emission wavelengths of 485 
and 530 nM respectively. Data were analyzed by 
taking the initial velocities and fitting to a matrix 
developed previously using the PrAMA technique. 
 
Calculation of Ki values 
The fractional inhibitor activity, If, was calculated 
by dividing the initial velocity from the FU vs. 
time graph obtained with inhibitor, vi, by the initial 
velocity without inhibitor, vo. All inhibition assays 
were performed at room temperature and the data 
fit to the following equation using Sigma Plot 
software: 
 (1) 
 
If is fractional inhibition, I is the inhibitor 
concentration and Kiapp is the inhibitor 
concentration that gives 50% inhibition. 
 
Mechanism of Inhibition- ADAM9 was diluted 
1:500 in buffer 25 mM Tris pH 8, 6 x 10-4 % Brij-
35 and 35 µl was added to a 96 well plate.  
Various concentrations of prodomain (2 µl 
volume) in 25 mM Tris-Cl, pH 8, 100 mM NaCl, 
10% glycerol, 4 mM TCEP, and 10 mM CaCl2 
was added to the enzyme and preincubation was 
carried out for 15 min. Then 33 µl of substrate (5-
100 µM) of PEPDab010 was added and 
fluorescence intensities were measured with 
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 5 
excitation at 485 nm and emission at 530 nm. The 
final concentration of prodomain ranged from 75-
4000 nM. Fluorescence vs. time was plotted and 
slopes were derived from straight line fits of initial 
velocities. The reciprocals of the velocities were 
plotted vs. the reciprocals of substrate squared 
since the normal Lineweaver-Burk plot gave 
curved lines. The initial velocities vs. substrate 
concentrations were fit as a family of curves to 
several allosteric models. The data fit best to a 
pure competitive model as described in equation 2 
where binding of inhibitor prevents substrate from 
binding to both sites.  
 
 (2) 
 
In this equation, v is the velocity obtained from the 
fluorescence units vs time plot, V is the maximum 
velocity, S is the substrate concentration, I is the 
inhibitor concentration, Ks is the dissociation 
constant for substrate binding to enzyme, and Ki is 
the inhibition constant. 
 
Cell culture- SH-SY5Y-APPswe neuroblastoma 
cells expressing APP with the Swedish mutation 
(APPswe: APPK595N, APPM596L) were cultured in 
DMEM supplemented with 10 % FBS, 2 mM 
Glutamin, and 400 µg/ml G418. For ADAM10 
and APP shedding analyses, cells were maintained 
in serum-free medium for 6 and 12 hours. Cell 
culture supernatants were analysed by western 
blotting and ELISA after concentrating using 
Vivaspin columns (Generon, UK) with an 
exclusion range of 20 kD.  
 
Western Blotting- For Western blot sample 
preparations, cell supernatants were concentrated 
and mixed with 5x SDS sample buffer (50% 
glycerol, 10% SDS, 100 mM β-mercaptoethanol, 
0.05% bromophenol blue in 250 mM Tris-HCl, pH 
6.8), boiled for 10 min and loaded onto 7.5% SDS-
PAGE for soluble APP detection. After gel runs, 
the proteins were blotted onto nitrocellulose 
transfer membranes (Protran BA79, 0.1 mm pore 
size, Schleicher & Schuell, Dassel, Germany) by 
tank blotting. After control staining with 0.1% 
Ponceau S solution and blocking for 2 h with 5% 
skim milk in TBS containing 0.1% Tween-20, 
proteins were analysed by immunostaining using 
antibodies described under materials in the given 
concentrations. 
 
ELISAs- Concentrations of sAPPβ were 
determined using the MSD sAPPß Assay and 
MSD Ab triplex assay as described by the 
manufacturer (Meso Scale Discovery, 
Gaithersburg, MD, USA). Concentrations of 
sAPPα were measured using a biotinylated-
antibody (clone 14D6) with the same specificity as 
the 4B4 [15]. The streptavidin pre-coated 96-well 
plates (MSD, L15SA-1/L11SA-1) were blocked 
with blocking solution for 30 minutes, washed 3 
times with Tris Wash Buffer and coated with the 
biotinylated antibody 14D6 for 1 hour. After 
washing 3 times, the wells were incubated with 25 
ml of standards or samples and 25 ml of the anti-
rabbit 5313 antibody for 2 hours. The wells were 
washed 3 times and incubated with 25 ml of MSD 
Sulfo-Tag goat-anti-rabbit-antibody (MSD, 
R32AB-5) as detection antibody. The wells were 
washed 3 times and incubated with the MSD Read 
Buffer T and the MSD plates were measured on 
the MDS Sector Image 600 plate reader. The raw 
data were measured as electrochemiluminescence 
signal detected by photodetectors. 
 
Statistical analysis- Data were presented as mean 
values ± standard deviation. The student’s t test 
was applied for data analysis. P values <0.05 were 
considered significant. 
 
Peptide Microarray experiments- BT474 breast 
tumor cells were obtained from ATCC and were 
grown in RPMI media containing 10% Fetal 
Bovine Serum. The cells were seeded at 1x106 
cells/ml plated in either 96 or 6 well plates. After 
overnight incubation cells were placed in 
Minimum Essential Media (MEM) without serum. 
Prodomain of ADAM9, ADAM10 or a buffer 
control were added to the media after filter 
sterilization with a 0.22 µm filter. The final 
concentration of glycerol was adjusted to 1%. 
After 24 hr, media was collected and frozen. The 
frozen media analyzed by RayBiotech in an L 
series 507 microarray. Data were normalized to 
both positive and negative controls that were run 
alongside samples. Each run represents averages 
of triplicate values after normalization. Ratios of 
control vs. treated were determined for two 
separate runs. Data were presented as mean 
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 6 
values. Values between 0.8 and 1.4 for an average 
of two runs indicates no change in factor levels 
while a value below 0.8 means a decrease of factor 
in the media for the treated cells. 
 
Results 
Generation and characterization of ADAM9 
prodomain- A bacterial expression construct for 
the prodomain of ADAM9 (proA9) was generated 
excluding the N-terminal hydrophobic signal 
sequence region and terminated at the furin 
cleavage site (aa 24-204 of mADAM9). A 
construct encoding a C-terminal His-tagged 
protein rendered a completely insoluble protein 
(data not shown), so that the N-terminal construct 
was used in all studies.   
Since the yield of recombinant protein was low (< 
50 µg/l), refolding of proA9 was done from 
inclusion bodies. Once refolded, samples were 
analyzed for protein content by SDS PAGE and 
for inhibitory potency against ADAM9 to assess if 
the prodomain had refolded properly (Table 1 and 
Fig. 1A). The optimal refolding conditions proved 
to be 50mM CHES, pH 9 with 5mM TCEP 
without arginine. 
ProA9 purified from the insoluble fraction after 
refolding, had identical properties to the proA9 
obtained from the soluble fraction (Figure 1B,C).  
Using this proA9 preparation, inhibition studies 
against several recombinant ADAM proteases 
were carried out to evaluate specificity. 
Recombinant proA9 is an efficient inhibitor of 
human ADAM9, with an apparent inhibition 
constant, Ki(app), of 280 ± 34nM (Figure 2A; Table 
2). ADAM8 and 12 are weakly inhibited by proA9 
with approximate apparent Kis in the micromolar 
range (>1µM and >6µM respectively). 
Recombinant ADAM10 and ADAM17/TACE 
proteases were not inhibited by proA9 even at 
concentrations of ≥ 8 µM (Table 1). Given these 
parameters, a low µM concentration of proA9 can 
be used in cell-based assays to inhibit ADAM9 
activity.  
 
Mechanism of Inhibition- ProA9 was tested to 
determine the mode of inhibition for human 
ADAM9. A typical Lineweaver-Burk plot, where 
the substrate was varied as a function of inhibitor 
concentration, gave curved lines for the reciprocal 
plot. Thus a 1/v vs. 1/[S2] plot was used and gave a 
good fit with varying slopes but the intercepts 
remaining the same (Figure 2B). This indicated 
that proA9 is a competitive inhibitor of ADAM9. 
This analysis also indicated that ADAM9 has at 
least two binding sites for the fluorescent 
substrate. The velocities vs. substrate at varying 
inhibitor values were fit as a family of curves to 
the pure competitive inhibitor model. The Ki, 
calculated with this method was 240 ± 110 nM 
and the binding constant, Ks for substrate was 37 ± 
9µM. The Ki is in close agreement to what was 
found for the apparent inhibition constant, Kiapp, 
calculated from the inhibition data eq (1). 
 
ProA9 inhibits ADAM10 shedding and increases 
alpha secretase activity on the cell membrane- In 
an earlier report, shedding of ADAM10 by 
ADAMs 9 and 15 was described, but the 
physiological consequences of this process remain 
elusive(21,22). We used the proA9 as a specific 
inhibitor to address this question. To provide 
direct evidence for ADAM9 regulating ADAM10 
activity, SH-SY5Y neuroblastoma cells over-
expressing APP were treated with proA9 at 
concentrations of 1 and 5 µM and the extent of 
soluble ADAM10 was determined by Western 
blotting using an antibody directed against the MP 
domain of ADAM10 (Fig. 3A). ADAM9 
inhibition by proA9 resulted in reduced release of 
soluble ADAM10 (30 ± 4% for 1 µM, 15 ± 5% for 
5 µM) in the media. Furthermore, a method 
developed previously, termed Proteolytic Activity 
Matrix Analysis (PrAMA)(30), was used to 
quantify the amount of proteolytically active 
ADAM10 in the media. PrAMA employs a panel 
of synthetic FRET-based polypeptide protease 
substrates to record a quantitative signature of 
cleavage rates for a given biological sample. Prior 
knowledge of individual MMP/ADAM cleavage 
specificity profiles measured with purified 
enzymes allows PrAMA to decipher specific 
enzyme (e.g., ADAM10) activities from observed 
cleavage signatures.  In this work, we used five 
different proteinase substrates as described in 
M&M that vary in their specificity for ADAMs 
and MMPs to infer the activities of MMP9, 
ADAM10, and ADAM17. PrAMA analysis 
confirmed a decrease in the amount of ADAM10 
activity in media from SY5Y cells with proA9 
treatment (Fig 3B), while no significant change in 
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MMP9 or ADAM17 activity was observed (data 
not shown).  These results demonstrate that 
inhibition of ADAM9 leads to a significant 
reduction of ADAM10 release and confirm 
previous findings that ADAM9 is a processing 
enzyme for ADAM10(21,22,31).  
 
We next tested whether this reduction caused an 
increase in the membrane associated activity of 
ADAM10. Western analysis and FRET assays of 
the membrane fraction were accomplished and 
analyzed by PrAMA. The amount of ADAM10 as 
measured by both of these techniques indicated an 
increase in the cellular fraction after proA9 
treatment of the SY5Y cells (Figure 3C).  As with 
analysis of the media, PrAMA did not detect 
significant changes in ADAM17 activity upon 
proA9 treatment. Since ADAM10 activity was 
increased on the membrane of cells given a 
specific inhibitor of ADAM9, the release of 
amyloid precursor protein (APP), a physiological 
substrate for ADAM10, was quantified by ELISA 
from SY5Y cells to determine if soluble APP 
levels increased in media from proA9 treated cells 
(Figure 4 A-C).  
Western analysis of whole cell lysate and 
supernatant from SY5Y cells after proA9 
treatment indicated similar amounts of APP 
(Figure 4A). However, when media was collected 
after 6 and 12 hour treatments with proA9 or a 
buffer control and the amounts of sAPPα and 
sAPPβ were analyzed via a multiplex ELISA, a 
dose dependent increase in sAPPα and 
corresponding decrease in sAPPβ was detected, 
indicating that the alpha secretase activity of 
ADAM10 can be regulated by specific inhibition 
of ADAM9 (Figure 4B,C).  
 
Peptide microarray screening- Having shown that 
ADAM9 regulates ADAM shedding activity, a 
protein array analysis was performed to obtain a 
more general screen on the regulation of ADAM9 
and ADAM10 activity in cancer cells. The Ray 
Biotech L series protein array was chosen because 
it had been successfully used in other published 
assays to quantify protein levels in samples from 
cell media or biological fluids (32). In the 
RayBiotech patented approach, media samples, 
either treated or buffer control, was biotin labeled 
and incubated on a glass chip printed with 507 
different antibodies. Briefly BT474 cells were 
treated with 5µM proA9. As a comparison to 
proA9 inhibition, proA10 was used as a specific 
inhibitor of ADAM10 dependent shedding events.  
Using this method, three different groups 
of proteins can be classified (Table 3): an increase 
in the media of physiological substrates for 
ADAM10 after proA9 treatment (proA10 
treatment resulted in a reduction of the same 
substrates), a decrease in the media of factors after 
proA9 but not proA10 inhibition, and an 
attenuation of factors found in the media after 
either proA9 or proA10 treatment.  
In the first group, endogenous shedding of 
known ADAM10 substrates such as Her2, 
osteoactivin, CD40-Ligand, and EGF were all 
downregulated by proA10 and upregulated by 
proA9 addition to the BT474 cells. In contrast, 
novel factors possibly shed by ADAM9 and not by 
ADAM10 were also found such as MAC-1, 
glucocorticoid-induced tumour necrosis factor 
receptor (GITR), platelet derived growth factor 
alpha (PDGF-Rα), and transforming growth 
factor-alpha (TGF-α). Several proteins decreased 
in the media from cells treated with either inhibitor 
such as neuropilin2, lipopolysaccharide binding 
protein (LBP), and OX40-ligand.  In addition, 
tumor necrosis factor receptor 1 (TNF-R1) and 
tumor necrosis factor-alpha (TNF)/amphiregulin 
(AR), physiological substrates for ADAM8 (33) 
and ADAM17 (34-36) respectively, were not 
affected by proA9 or proA10 treatments, 
indicating that the inhibitors are quite selective in 
their actions (data not shown).  
 
Discussion 
With respect to the selectivity of proA9, 
the observed IC50 for inhibition of ADAM8 is 
slightly higher than 1µM (see table 2), so the Ki 
difference is about 5-fold. However it is likely that 
some inhibition of ADAM8 may occur at 5µM 
proA9 concentration, even though in BT474 cells, 
the presence of both L-selectin and TNF-R1 in the 
media, two substrates for ADAM8 is not affected 
by proA9 treatment. This could be due to  
very low ADAM8 levels in BT474 cells that was 
confirmed by RNA analysis and by a PrAMA 
experiment where the substrate specific for 
ADAM8 (PEPDab013) is only slightly 
processed in both membrane and media samples, 
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even though other less selective substrates with the 
same kcat/Km for ADAM8 are processed very well 
(data not shown). 
Since ADAM10 has been described as the 
essential α-secretase in neurons, the control of 
neuronal ADAM10 activity has crucial importance 
in the aetiology of AD (20) and attempts to raise 
cellular ADAM10 levels have been considered as 
potential therapeutic strategies in AD (19). We 
found that specific proA9 mediated inhibition of 
ADAM9 catalytic activity in SY5Y neuroblastoma 
cells regulates ADAM10 activity on the cell 
membrane by preventing its proteolytic release. 
Because the amount of membrane bound 
ADAM10 increases when its shedding is reduced, 
we postulate that the enzyme’s cleavage activity 
would correspondingly be increased. In 
accordance with these findings, proA9 inhibition 
of ADAM9, a principal sheddase for ADAM10, 
leads to an increase in the alpha secretase activity 
for APP in cell based assays, increasing the 
extracellular levels of sAPPα, arguing for an 
inhibition of ADAM9 to favor a non-
amyloidogenic pathway. Since ADAM9 is 
dispensable in vivo as shown by ADAM9 deficient 
mice(37), this therapeutic strategy seems to be 
feasible.  
In previous studies loss and gain of 
function assays were performed in transfected 
cells and demonstrated that ADAM9 indirectly 
increases the amount of sAPPα likely through 
cleavage of ADAM10. Our findings demonstrate 
that an immediate reduction in soluble ADAM10 
by inhibition of ADAM9 catalysis increases 
ADAM10 processing of APP at the alpha cleavage 
site. This complements more long-term 
experiments that require longer periods to 
constitute a complex interplay of ADAM proteins 
after knockdown (21) or over-expression of 
ADAM9 in the presence of siRNA for ADAM10 
(31). In addition, we demonstrate the effect of 
endogenous inhibition of ADAM9 rather than a 
reduction in its activity after transfection.  
Further proof that ADAM9 inhibition 
leads to an increase in membrane ADAM10 
activity arises from results with the BT474 tumor 
cells where increased levels of proteins for proven 
substrates of ADAM10 were found in the media 
from proA9 treated cells. Of 507 different factors 
that can be detected in media samples by the 
microarray approach, only a handful are secreted 
at reduced levels and several are type I or II 
membrane proteins capable of serving as 
substrates for ADAM9. These factors range from 
receptors to growth factors. The mechanism by 
which proA9 specifically reduces type I and II 
integral membrane protein levels in the media is 
likely due to its inhibition of ADAM9 catalytic 
activity as it is a competitive inhibitor. In contrast, 
proA10 treatment affects ADAM10 dependent 
shedding events (over 100 factors are reduced in 
the media from BT474 treated cells; data not 
shown) but has no effect in parallel assays on the 
newly identified potential substrates for ADAM9. 
These results indicate that generally specific 
inhibition of ADAM9 controls membrane 
ADAM10 activity which could be of general in 
vivo relevance.   
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Footnotes 
 
1 The Abbreviations used are: aa, amino acid; ADAM, a disintegrin and metalloproteinase; CM, 
conditioned media; Dabcyl, 4-(4-Dimethylaminophenylazo)benzoyl; DMSO, dimethyl sulfoxide; 
EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; Fam, 5-carboxyfluorescein; 
GITR, glucocorticoid-induced tumour necrosis factor receptor; IPTG, isopropyl-β-D-
thiogalactopyranoside; LBP, lipopolysaccharide binding protein; mEF, mouse embryonic fibroblast; 
PDGF-Rα, platelet derived growth factor alpha; PEPDab005, Dabcyl-Leu-Ala-Gln-Ala-Homophenyl-
Arg-Ser-Lys(Fam)- NH2; PEPDab008, Dabcyl-Pro-Cyclohexyl-Gly-Cys(Me)-His-Ala-Lys(Fam)-
NH2; PEPDab010, Dabcyl-Ser-Pro-Leu-Ala-Gln-Val-Arg-Ser-Ser-Lys(Fam)- NH2; PEPDab013, 
Dabcyl-His-Gly-Asp-Gln-Met-Ala-Gln-Lys-Ser-Lys(Fam)-NH2; PEPDab014, Dabcyl-Glu-HisAla-
Asp-Leu-Leu-Ala-Val-Val-Ala-Lys(Fam)-NH2;  ProA9, prodomain of ADAM9; ProA10, prodomain 
of ADAM10; TACE, tumor necrosis factor-alpha converting enzyme; TCEP, tris(2-
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carboxyethyl)phosphine; TNF-R1, p55 tumor necrosis factor receptor 1; TNF, tumor necrosis factor; 
TGF-α, transforming growth factor-alpha.  
 
 
Figure Legends 
 
Figure 1: Purification and characterization of proA9 from inclusion bodies.  (A) SDS-polyacrylamide 
gel of proA9 refolded in a variety of buffers. The band corresponding to the proA9 recombinant 
protein. ProA9 was prepared under different pH and redox conditions shown in table 1; R, arginine 
added to buffers; Redox, glutathione oxidized and reduced mixture; (B) SDS-polyacrylamide gel of 
proA9 purified from the soluble fraction by Talon resin chromatography and Superdex 75 
fractionation. (C) SDS-polyacrylamide gel of proA9 purified from inclusion bodies. Lane 1, insoluble 
fraction following pressure-mediated refolding of proA9 inclusion body protein; lane 2, soluble 
fraction; lane 3, Ni-chelating chromatography pool; lane 4, Sephacryl 200 pool; lane 5, proA9 
following endotoxin removal.  
 
Figure 2:  (A) Plot of vi/vo against concentration of proA9 (I) in nM. The IC50 is plotted a dotted line. 
(B) Lineweaver-Burk plot of 1/v vs 1/S2 in the presence of various concentrations of proA9.  
Symbols:      600nM,      300nM,      150nM,       75nM,      0nM. 
 
Figure 3: Inhibition of ADAM10 shedding by proA9 in SY5Y cells and regulation of ADAM10 alpha 
secretase activity.  (A) Western blot of soluble ADAM10 in supernatants of SY5Y cells. Cells were 
incubated for 24 hours untreated (“ctrl”), with buffer control (corresponding to the proA9 volume of 5 
µM), with 500 nM BB-94, 500 ng hTIMP-1 or proA9 in concentrations of 1 (“ProA9 (1)”) and 5 
(“proA9 (5)”) µM, respectively. Supernatants were concentrated and precipitated with TCA. Samples 
were resuspended in Laemmli buffer and separated on 10% polyacrylamide gels. Blots were 
incubated with anti-ADAM10 detecting the extracellular portion of ADAM10. A 55kD band 
represents the soluble form of ADAM10, containing the MP and parts of the disintegrin domain, in 
agreement with the data published earlier (22). (B) Membrane-associated (“M”) and soluble 
ADAM10 (“S”) activities in the absence (“ctrl”) and presence of 5 µM proA9 (“proA9”) were 
analysed by PrAMA as described in the M&M section. Fluorescence values are given as mean values 
± SD from 3 independent experiments. *, p<0.05. (C) Detection of membrane-associated ADAM10 
in SY5Y cells. Cells treated with buffer (“ctrl”) or 5 µM proA9 (“proA9”) were lysed and membranes 
were isolated as described in M&M. After protein concentrations were determined, identical 
concentrations of membrane preparations were analyzed by western blotting using anti-ADAM10 
antibody.  
 
Figure 4: Effect of proA9 on APP shedding in SH-SY5Y cells overexpressing APP(swe). (A) 
Western blot analysis of APP in whole cell lysates (“WCL”) and in supernatants (“SN”). Note that in 
the supernatant, APP α and β is detected; (B) and (C), MSD ELISAs (Meso Scale Discovery) were 
used to determine the concentrations of soluble APP-alpha (sAPPα; B) and soluble APP-beta (sAPPβ; 
C). The electric signal measured with the ELISA was converted into concentrations in [pg/ml] by 
using calibration curves for each individual analysis. The values given are derived from 2 sets of 
quadruplets (n=8) and are given as mean ± SD. Statistical significance was determined using 
Student’s t-test and values are provided as highly significant (***, p<0.001, **, <0.01, *, p<0.05). 
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Table 1: Corresponding inhibitory activity of ADAM9 using a fixed volume of buffer containing 
proA9 from different refolding conditions. Refolding conditions for proA9 varied in pH values, 
presence of arginine (R), and/or glutathione oxidized and reduced mixture (“Redox”). Note that 
identical sample numbers 1-13 are shown in lanes figure 1A.  
 
 
 
 
 
 
 
 
Lane # 
 
Sample ID  % Inhibition 
1 pH8 75 
2 pH9 97 
3 pH6 +R 22 
4 pH7 +R 75 
5 pH8 +R 89 
6 pH9 +R 84 
7 pH9 +Redox 60 
8 pH8 +R+Redox 42 
9 pH7 +0.5xR 69 
10 pH7 +0.25xR 71 
11 pH7 +0.1xR 77 
12 pH8 +0.5xR 93 
13 pH8 +0.25xR  0 
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Table 2: Inhibition of protease activity by proA9 for different recombinant ADAM proteins.  
ProA9 was incubated with the human recombinant ADAM proteins indicated and the amount of 
inhibition was determined by fluorometric assay as described in M&M section.  
Rec. Protease ProA9 Ki  [nM] 
ADAM8 > 1000 
ADAM9 280± 34 
ADAM10 > 8000 
ADAM12 >6000 
ADAM17 > 8000 
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Factor Description Disease 
association 
Ratio 
pA9/buffer 
control 
Ratio 
pA10/buffer 
control 
Ref. 
Group I      
ErbB2 Receptor tyrosine 
kinase 
Cancer  2.5± 1.0 0.6±0.1 (24) 
CD40-L  Inflammation  2.0±0.4 0.3±0.1 (38) 
Osteoactivin Transmembrane 
glycoprotein 
NMB (GPNMB) 
Cancer 2.5±0.5 0.60±0.1 (39,40) 
EGF Epidermal 
Growth Factor 
Cancer 3.3±1.2 0.6±0.1 (41) 
GroupII      
GITR ligand 
 
Glucocorticoid-
induced tumour 
necrosis factor 
receptor (GITR) 
ligand 
Inflammatory 
activation of 
macrophages 
0.3±0.1 0.9±0.1 (42) 
MAC-1 
 
Complement 
receptor (CR3) 
Inflammatory 
diseases, viral 
infection 
0.5±0.1 1.4±0.1 (43-45) 
PDGF-Rα 
 
Tyrosine kinase 
receptor for 
platelet derived 
growth factor 
alpha 
Cancer 0.5±0.1 1.1±0.3 (46) 
TGF-α Epidermal growth 
factor ligand 
family member 
Cancer 0.2±0 1.4±0.2 (47) 
GroupIII      
LBP 
 
Binds Lipopoly-
saccaride/ Acute 
phase protein 
localized 
defense to 
Gram negative 
bacteria 
0.3±0.1  0.5±0.2 (48) 
MT3-MMP 
 
Membrane type 3-
Matrix 
metalloproteinase  
Cancer 0.3±0.1 <0.1 (49) 
Neuropilin-2 
 
Receptor for 
semaphorins and 
VEGF 
Cancer 0.6±0.3 0.3±0.1 (50-52) 
 
Table 3: Ratios of Type I and II integral membrane proteins in media after proA9 and proA10 
treatment of BT474 cells. ProA9 (5µM) or ProA10 (23-213 wild type, 10µM) and corresponding 
buffer controls were incubated alongside with BT474 cells for 24 hr in serum free conditions. 
Media were collected and analyzed by the RayBiotech 507 L series microarray. Data represents 
the average ratio from two independent runs done in triplicate.  
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